To assess the effects of cholinesterase inhibitors huperzine A, donepezil and rivastigmine on cerebral neurotransmitters in the cortex and hippocampus in freely-moving rats.
Double-probe cerebral microdialysis and HPLC with electrochemical detection were used to detect neurotransmitters.
Our results showed that huperzine A (0.25, 0.5, and 0.75 μmol/kg, po) dose-dependently elevated extracellular acetylcholine (ACh) levels in the medial prefrontal cortex (mPFC) and hippocampus. Oral administration of donepezil (5.4 μmol/kg) or rivastigmine (1 μmol/kg) also elicited significant increases in ACh in the mPFC and hippocampus. The time course of cortical acetylcholinesterase (AChE) inhibition with the 3 inhibitors mirrored the increases of ACh at the same dose. The marked elevation of ACh after oral administration of huperzine A (0.5 μmol/kg) and donepezil (5.4 μmol/kg) was associated with a significantly increased release of dopamine (DA) in the mPFC or hippocampus. None of the 3 inhibitors affected norepinephrine (NE) and 5-hydroxytryptamine (5-HT) levels in the mPFC and hippocampus. The effects of huperzine A and rivastigmine did not depend on the route of administration, but donepezil was less efficacious by the oral route than by ip injection. The ability of huperzine A to increase ACh levels was unchanged when tests were performed after multiple oral administration of the drug at 0.5 μmol/kg, once per day for 30 d.
The present findings showed that, in molar terms, huperzine A had similar potency on increasing mPFC ACh and DA levels as compared to the 11- and 2-fold dosages of donepezil and rivastigmine, respectively, and had longer lasting effects after oral dosing.
Alhainen K, Helkala EL, Reinikainen K, Riekkinen, P Sr . The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm 1993; 5: 185–92.
Barili P, De Carolis G, Zaccheo D, Amenta F . Sensitivity to ageing of the limbic dopaminergic system: a review. Mech Ageing Dev 1998; 106: 57–92.
Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, et al. Kinetic and structural studies on the interaction of cholinesterase with the anti-Alzheimer drug rivastigmine. Biochemistry 2002; 41: 3555–64.
Bradford MM . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54.
Brozoski T, Brown RM, Rosvold HE, Goldman PS . Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979; 205: 929–32.
Costa LG, Schwab BW, Murphy SD . Tolerance to anticholinest-erase compounds in mammals. Toxicology 1982; 25: 79–97.
Coyle JT, Price DL, DeLong MR . Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184–90.
Cuadra G, Summers K, Giacobini E . Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacal Exp Ther 1994; 270: 277–84.
Davidson M, Bierer LM, Kaminsky R, Ryan TM, Davis KL . Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer Disease Assoc Disorders 1989; 3: 224–7.
Day J, Fibiger HC . Dopaminergic regulation of cortical acetylcholine release. Synapse 1992; 12: 281–6.
Decker MW, McGaugh JL . The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991; 7: 151–68.
Ellman GL, Courtney KD, Andre V Jr, Featherstone RM . A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88–95.
Floresco SB, Seamans JK, Phillips AG . Selective roles for hippocampal, refrontal cortical, and ventral striatal circuits in radial-arm maze tasks with or without a delay. J Neurosci 1997; 17: 1880–90.
Giacobini E, Becker R . Development of drugs for Alzheimer therapy: a decade of progress. In: Giacobini E, Becker, R Alzheimer Disease: Therapeutic Strategies. Boston, MA: Birkhäuser Press; 1994. p 1–7.
Giacobini E, Cuadra G . Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. In: Giacobini E, Becker, R Alzheimer Disease: Therapeutic Strategies. Boston, MA: Birkhäuser Press; 1994. p 155–71.
Giacobini E, Zhu XD, Williams E, Sherman KA . The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996; 35: 205–11.
Hallak M, Giacobini E . Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989; 28: 199–206.
Haroutunian V, Santucci AC, Davis KL . Implications of multiple transmitter system lesions for cholinominetic therapy in Alzheimer's disease. Prog Brain Res 1990; 84: 333–46.
Hersi AI, Rowe W, Gaudreau P, Quirion R . Dopamine D1 receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory-impaired aged rats. Neuroscience 1995; 69: 1067–74.
Jann MW . Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000; 20: 1–12.
Kosasa T, Kuriya Y, Matsui K, Yamanishi Y . Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 1999; 380: 101–7.
Laganiere S, Corey J, Tang XC, Wulfert E, Hanin I . Acute and chronic studies with the anticholinesterase huperzine A: effect on central nervous system cholinergic parameters. Neuropharmacology 1991; 30: 763–9.
Levy A, Kong RM, Stillman MJ, Shukitt-Hale B, Kadar T, Rauch TM, et al. Nimodipine improves spatial working memory and elevates hippocampal acetylcholine in young rats. Pharmacol Biochem Behav 1991; 39: 781–6.
Marien MR, Colpaert FC, Rosenquist AC . Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Rev 2004; 45: 38–78.
McCarthy G, Blamire AM, Puce A . Functional magnetic resonance imaging of human prefrontal cortex activation during a spatial working memory task. Proc Natl Acad Sci USA 1994; 91: 8690–4.
Pang YP, Kozikowski AP . Prediction of the binding site of huperzine A in acetylcholinesterase by docking studies. J Comput Aided Mol Des 1994; 8: 669–81.
Paxinos G, Watson, C The rat brain in stereotaxic coordinates. Sydney: Academic Press; 1997.
Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman JL . Structure of acetylcholinesterase complexed with the nootropic alkaloid (-)-huperzine A. Natural Struct Biol 1997; 4: 57–63.
Scali C, Casamenti F, Pazzagli M, Bartolini L, Pepeu G . Nerve growth factor increases extracellular acetylcholine levels in the parietal cortex and hippocampus of aged rats and restores object recognition. Neurosci Lett 1994; 170: 117–20.
Steckler T, Sahgal A . The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav Brain Res 1995; 67: 165–99.
Sugimoto H, Ogura H, Arai Y, Limura Y, Yamanishi Y . Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol 2002; 89: 7–20.
Taghzouti K, Le Moal, M, Simon H . Dopaminergic innervation of the lateral septum and learning processes. Neurosci Lett Suppl 1986; 26: s332.
Tang XC . Huperzine A (Shuangyiping): A promising drug for Alzheimer's disease. Acta Pharmacol Sin 1996; 17: 481–4.
Tang XC, De Sarno P, Sugaya K, Giacobini E . Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989; 24: 276–85.
Taylor P . Anticholinesterase agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman, AG The pharmacological basis of therapeutics. New York: McGraw-Hill; 1996. p 161–76.
Trabace L, Coluccia A, Gaetani S, Tattoli M, Cagiano R, Pietra C, et al. In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus. Brain Res 2000; 865: 268–71.
Wang R, Yan H, Tang XC . Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006; 27: 1–26.
Weinstock M, Razin M, Chorev M, Enz A . Pharmacological evaluation of phenylcarbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm 1994; 43: 219–25.
Zhu XD, Giacobini E . Second generation cholinesterase inhibitors: effect of (L)-huperzine A on cortical biogenic amines. J Neurosci Res 1995; 41: 828–35.
Project supported by the National Natural Science Foundation of China (No 30123005).
About this article
Cite this article
Liang, Yq., Tang, Xc. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sin 27, 1127–1136 (2006). https://doi.org/10.1111/j.1745-7254.2006.00411.x
- huperzine A
- 5-hydroxy tryptamine
- Alzheimer's disease
Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats
Naunyn-Schmiedeberg's Archives of Pharmacology (2016)
Phytochemistry Reviews (2016)
Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex
High level interleukin-6 in the medium of human pancreatic cancer cell culture suppresses production of neurotransmitters by PC12 cell line
Metabolic Brain Disease (2012)
Chinese Medicine (2011)